WallStSmart

Integer Holdings Corp (ITGR)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 3043% more annual revenue ($57.36B vs $1.83B). NVS leads profitability with a 17.5% profit margin vs 5.7%. ITGR appears more attractively valued with a PEG of 2.81. NVS earns a higher WallStSmart Score of 48/100 (D+).

ITGR

Hold

41

out of 100

Grade: D

Growth: 4.0Profit: 5.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 1.93

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ITGRUndervalued (+6.6%)

Margin of Safety

+6.6%

Fair Value

$93.36

Current Price

$126.42

$33.06 discount

UndervaluedFair: $93.36Overvalued
NVSSignificantly Overvalued (-69.8%)

Margin of Safety

-69.8%

Fair Value

$95.76

Current Price

$160.32

$64.56 premium

UndervaluedFair: $95.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ITGR1 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$303.67B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.3%10/10

Strong operational efficiency at 34.3%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

Areas to Watch

ITGR4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.934/10

Grey zone — moderate risk

Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.812/10

Expensive relative to growth rate

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ITGR

The strongest argument for ITGR centers on Price/Book.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.

Bear Case : ITGR

The primary concerns for ITGR are Altman Z-Score, Profit Margin, Piotroski F-Score. A P/E of 42.5x leaves little room for execution misses.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Key Dynamics to Monitor

ITGR carries more volatility with a beta of 0.58 — expect wider price swings.

NVS is growing revenue faster at 4.7% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (48/100 vs 41/100), backed by strong 17.5% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Integer Holdings Corp

HEALTHCARE · MEDICAL DEVICES · USA

Integer Holdings Corporation is an outsourced manufacturer of medical devices in the United States, Puerto Rico, Costa Rica, and internationally. The company is headquartered in Plano, Texas.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?